NeuroOne Medical Technologies (NASDAQ:NMTC) Releases Quarterly Earnings Results

NeuroOne Medical Technologies (NASDAQ:NMTC) released its earnings results on Thursday. The company reported ($0.28) EPS for the quarter, beating analysts’ consensus estimates of ($0.58) by $0.30, FiscalAI reports. NeuroOne Medical Technologies had a negative return on equity of 99.43% and a negative net margin of 68.35%.The firm had revenue of $1.97 million for the quarter, compared to analysts’ expectations of $2.55 million.

Here are the key takeaways from NeuroOne Medical Technologies’ conference call:

• Third-quarter product revenue rose 16% year over year to $2.0 million, while product orders increased 43% to $2.7 million. Gross margin also expanded to 59.9% from 53.9%, driven by a favorable product mix.
• Manufacturing constraints left a $1.7 million backlog and caused management to lower expected fiscal 2026 recognized revenue to $9.2 million-$10.5 million, despite approximately $11.2 million in expected orders. A second, larger manufacturing site is targeted for early 2027.
• NeuroOne received ISO 13485 certification, enabling international commercialization of its OneRF Brain Ablation, OneRF Trigeminal Nerve Ablation, and Evo diagnostic product lines. The company plans to work with Zimmer Biomet and independent distributors to enter selected markets.
• The company reported progress across its pipeline, including clinical support for OneRF in patients with existing neuromodulation implants, expansion of trigeminal nerve ablation distribution, and preclinical collaborations for the StereoCED drug-delivery platform. StereoCED is expected to be ready for investigational human studies by the end of September, while the BVNA back-pain system is targeted for a 510(k) submission in the second half of calendar 2027.
• Cash and equivalents declined to $2.0 million as of June 30 from $6.6 million at fiscal year-end, while the quarterly net loss widened to $2.0 million from $1.5 million. The company raised $0.4 million during the quarter and another $1.0 million after quarter-end through its ATM program, indicating continued reliance on equity financing.

NeuroOne Medical Technologies Trading Up 10.1%

Shares of NASDAQ NMTC traded up $0.18 during trading hours on Friday, reaching $2.02. The stock had a trading volume of 71,865 shares, compared to its average volume of 46,205. NeuroOne Medical Technologies has a 52-week low of $1.42 and a 52-week high of $6.96. The firm has a market cap of $17.53 million, a price-to-earnings ratio of -2.37 and a beta of 0.61. The business’s fifty day moving average price is $2.57 and its two-hundred day moving average price is $3.80.

Analyst Ratings Changes

A number of brokerages recently issued reports on NMTC. Maxim Group set a $5.00 price target on NeuroOne Medical Technologies in a research note on Friday. LADENBURG THALM/SH SH upped their price objective on NeuroOne Medical Technologies from $1.60 to $8.00 and gave the company a “buy” rating in a research report on Wednesday, May 13th. Finally, Weiss Ratings upgraded NeuroOne Medical Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Tuesday, July 28th. Three analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Hold” and an average target price of $7.33.

Insider Buying and Selling

In other NeuroOne Medical Technologies news, Director Mark Christianson sold 10,000 shares of NeuroOne Medical Technologies stock in a transaction on Tuesday, June 30th. The stock was sold at an average price of $3.18, for a total transaction of $31,800.00. Following the completion of the sale, the director directly owned 20,692 shares of the company’s stock, valued at $65,800.56. The trade was a 32.58% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. 11.80% of the stock is owned by insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in NMTC. Vanguard Group Inc. increased its position in NeuroOne Medical Technologies by 31.2% during the 3rd quarter. Vanguard Group Inc. now owns 1,578,237 shares of the company’s stock valued at $1,403,000 after purchasing an additional 375,639 shares during the period. Essex Investment Management Co. LLC purchased a new stake in shares of NeuroOne Medical Technologies in the 4th quarter worth approximately $143,000. Virtu Financial LLC bought a new position in shares of NeuroOne Medical Technologies during the third quarter valued at approximately $88,000. Goldman Sachs Group Inc. bought a new position in shares of NeuroOne Medical Technologies during the first quarter valued at approximately $84,000. Finally, XTX Topco Ltd purchased a new position in NeuroOne Medical Technologies during the second quarter valued at approximately $51,000. 16.07% of the stock is currently owned by institutional investors.

About NeuroOne Medical Technologies

NeuroOne Medical Technologies Corp. is a medical device company focused on developing advanced neural interface technologies for diagnostic and therapeutic applications in neurosurgery and neurology. The company’s core mission is to improve patient outcomes through next-generation electrode systems that enable high-resolution neural recording and targeted stimulation. By leveraging proprietary thin-film microelectrode arrays, NeuroOne aims to offer clinicians unprecedented single-unit precision during brain mapping procedures.

The company’s flagship platform, the EVO™ system, integrates thin-film neural electrodes with intraoperative monitoring hardware and software.